- 23 Downloads
In a case series, a 22-year-old woman developed resistance and cutaneous adverse reactions following off-label treatment with dabrafenib and trametinib, and a 22-year-old man developed resistance and photosensitivity rash following off-label treatment with vemurafenib and cobimetinib for glioblastoma [routes, duration of treatments to reactions onsets and outcomes not stated].
A 22-year-old woman presented with headache, which she had been suffering from three months. Craniotomy was performed and the diagnosis of isocitrate dehydrogenase-1 (IDH-1) wildtype, MGMT promoter methylated epithelioid glioblastoma with BRAFV600E mutation was made. She developed hydrocephalus and underwent ventriculoperitoneal shunting. Then, the shunt became block within a week and required external ventricular drainage (EVD). Her consciousness deteriorated and required nasogastric tube feeding. Due to the BRAFV600Emutation, she started receiving off-label treatment with trametinib 4mg daily along with...
- Woo PYM, et al. Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: A report of two cases. Oncotarget 10: 3818-3826, No. 38, 04 Jun 2019. Available from: URL: http://doi.org/10.18632/oncotarget.26932 - Hong Kong